A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction.
Tita C, Gilbert EM, Van Bakel AB, Grzybowski J, Haas GJ, Jarrah M, Dunlap SH, Gottlieb SS, Klapholz M, Patel PC, Pfister R, Seidler T, Shah KB, Zieliński T, Venuti RP, Cowart D, Foo SY, Vishnevsky A, Mitrovic V.
Tita C, et al. Among authors: pfister r.
Eur J Heart Fail. 2017 Oct;19(10):1321-1332. doi: 10.1002/ejhf.897. Epub 2017 Jul 5.
Eur J Heart Fail. 2017.
PMID: 28677877
Free PMC article.
Clinical Trial.